<SEC-DOCUMENT>0001140361-21-036477.txt : 20211104
<SEC-HEADER>0001140361-21-036477.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211103214904
ACCESSION NUMBER:		0001140361-21-036477
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKET PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		211377714

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		646-440-9100

	MAIL ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOTEK PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20040226
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10030396_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:rckt="http://rocketpharma.com/20211103" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_944bc0aef3cb4174950264ab04becc74" contextRef="c20211103to20211103" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b48c9520a2c348a1b56780cdea1ae5fa" contextRef="c20211103to20211103">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_98d2cd2eb343466ca3784513905cfb53" contextRef="c20211103to20211103">0001281895</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rckt-20211103.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20211103to20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, DC 20549</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_6f1d23abc01e4157aae70e9b707453c4" contextRef="c20211103to20211103">8-K</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to Section 13 or 15(d) of</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">The Securities Exchange Act of 1934</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
<div><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_f8fc90c4ce9342718b0519da845612b4" contextRef="c20211103to20211103" format="ixt:datemonthdayyearen">November 3, 2021</ix:nonNumeric></div>

      <div><br />
      </div>

    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_dad36ab69fb6437bb28e010c1f63bf51" contextRef="c20211103to20211103">Rocket Pharmaceuticals, Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_d68075168c8a45ef938be564446fd2bc" contextRef="c20211103to20211103" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a908c921b7de4f2f8ad25225f0f4033a" contextRef="c20211103to20211103">001-36829</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.32%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_b48c9520a2c348a1b56780cdea1ae5fa">04-3475813</span><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.34%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 33.32%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_6c07395c000a405e980479ccffceeb60" contextRef="c20211103to20211103">9 Cedarbrook Drive</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_b5c7a0d9cc8d44eba37c3ee2714e05d0" contextRef="c20211103to20211103">Cranbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_bd44b78ba0a34ad7a78e531c30b1fca6" contextRef="c20211103to20211103">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_e888262174d04a839250db071dba54fa" contextRef="c20211103to20211103">08512</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of principal executive offices, including zip code)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_c4605771fcfe43c799a64fbfd1abf696" contextRef="c20211103to20211103">646</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_3dbba35d95a5497da2b37a5084e4a45b" contextRef="c20211103to20211103">440-9100</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s telephone number, including area code)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not applicable</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
      (see General Instruction A.2):</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_ad119c79dd3a4b049bd1e0e15d1ae439" contextRef="c20211103to20211103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_20e409d334da43de86e3e6cc82572481" contextRef="c20211103to20211103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_dcf8ca17e5374636a3d7e1c0d69e47b3" contextRef="c20211103to20211103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_a469b6f38976430fb924a7f149b36df8" contextRef="c20211103to20211103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trading</div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Symbol(s)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d5bf7b018c9c4b32948d10bea750f018" contextRef="c20211103to20211103">Common stock, $0.01 par value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_f6e5f288615a45a3b079e3cb0d3af6a9" contextRef="c20211103to20211103">RCKT</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_40553ed7e99e47f3b43f134a67a44e38" contextRef="c20211103to20211103" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2
      of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_4b8fa9b47df24d6fb673ddda66431986" contextRef="c20211103to20211103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span>&#9744;</div>

    <div><br />
    </div>

    <div style="text-align: left;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 2.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Results of Operations and Financial Condition.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On November 3, 2021, Rocket Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September 30, 2021. A copy of
      the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</div>

    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed &#8220;filed&#8221;
      for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">&#160;</span></span>Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be
      deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(d) Exhibits.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10030396_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 92%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Press Release, dated November 3, 2021</div>
          </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">104</div>
          </td>

    <td style="width: 92%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 20pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: bottom;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Rocket Pharmaceuticals, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 52%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: bottom;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Date: November 3, 2021</div>
          </td>

    <td style="width: 3%; vertical-align: bottom;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 52%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">/s/ Gaurav Shah, MD</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 52%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Gaurav Shah, MD</div>
          </td>

  </tr>

  <tr>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 52%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Chief Executive Officer and Director</div>
          </td>

  </tr>


</table>
  </div>

  <div><br /></div>

  <div><br />
  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10030396_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div><br>
  </div>
  <div><img src="image00001.jpg"></div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212; Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501&#8212;</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8212;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; color: rgb(29, 28, 29);"> Treatment completed in nine of nine patients in LAD-1 Phase 1/2 trial; favorable safety profile and initial clinical benefit reported in all seven patients with at least 3 months of follow up</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8212; </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Clinical
        updates anticipated in Danon Disease at AHA 2021 Scientific Sessions and in FA, LAD-I and PKD at 63rd ASH Annual Meeting</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212; Ending Balance Sheet with $421.5 Million in Cash; Cash Runway Expected into 2H&#8217;23 &#8212;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CRANBURY, NJ </font>&#8211; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">November 3, 2021 </font>&#8211; <u>Rocket Pharmaceuticals, Inc.</u> (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial
      results for the quarter ending September 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;We are excited about the strong progress we made in the third quarter as we initiated treatment in our trial of RP-A501 for Danon Disease in the low-dose (6.7e13 vg/kg)
      pediatric patient cohort,&#8221; said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. &#8220;I am proud of our team&#8217;s collaboration with the FDA, through which we were able to swiftly resolve the clinical hold on the Danon trial and resume this
      highly important work on behalf of Danon patients. We are gearing up for the remainder of 2021 and look forward to reporting a comprehensive clinical update on our Phase I trial in Danon Disease this month at the AHA Scientific Sessions as well as
      key updates on all five of our first-in-class gene therapy programs throughout the fourth quarter.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Shah continued, &#8220;We are equally excited about the progress of our LAD-I program, where we completed treatment for all nine patients in the RP-L201 Phase 1/2 clinical
      trial and presented positive interim data updates on the initial seven patients at the ESGCT Congress in October. Based on the data presented from these seven patients, RP-L201 continues to demonstrate a favorable safety profile and preliminary
      clinical benefit in patients with severe LAD-I. We will share additional clinical data from the LAD-I trial at the 63<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> ASH Annual Meeting in December, where we will also report clinical updates on our Fanconi Anemia and PKD programs. I am
      proud of the Rocket team&#8217;s unwavering dedication to developing and bringing life-changing curative therapies to patients with rare diseases.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Key Pipeline and Operational Updates</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Danon Disease:</u></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z124a9c16140349b29979f963b67623ef">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Initiated pediatric patient treatment in Phase 1 trial of RP-A501 for the treatment of Danon
                Disease. </font>Rocket has resumed patient enrollment and initiated treatment in the low-dose (6.7e13 vg/kg) pediatric patient cohort. A comprehensive clinical update is anticipated at the American Heart Association (AHA) Scientific
              Sessions 2021 being held virtually November 13-15, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div> <img src="image00001.jpg"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z95679389227941228e74e711c8d00765">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presented previously disclosed data from ongoing RP-A501 Phase 1 trial in Danon Disease at HFSA. </font>The
              late-breaking oral presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font>overviewed data from the low-dose (6.7e13 vg/kg) adult cohort
              which demonstrated RP-A501 was well tolerated and showed progressive and durable clinical benefit.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Leukocyte Adhesion Deficiency-I (LAD-I):</u></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z736e9ce4549a4b1ea00bf7acc675cf71">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presented positive interim data updates from RP-L201 LAD-I trial at ESGCT. </font>The oral
              presentation included data from the initial seven patients with severe LAD-I who were treated with RP-L201 in the Phase 1/2 trial. The safety profile of RP-L201 appears favorable with all infusions well tolerated and no drug product-related
              serious adverse events. Preliminary efficacy was evident in all seven patients, including two patients with at least 12 months of follow-up. All seven patients demonstrated durable neutrophil CD18 expression that exceeded the 4-10% threshold
              associated with survival into adulthood and consistent with reversal of the severe LAD-I phenotype. Peripheral blood vector copy number (VCN) levels have been stable and in the 0.5 &#8211; 2.5 copy per genome range. No patients have had LAD-I
              related infections requiring hospitalization subsequent to hematopoietic reconstitution post RP-L201. Additional clinical data are anticipated at the 63<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> American Society of Hematology (ASH) Annual Meeting being held December
              11-14, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Fanconi Anemia (FA):</u></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ef807ef31a244e8a0eae5fa6ca7920b">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presented previously disclosed clinical data from RP-L102 Fanconi Anemia (FA) program at ESGCT. </font>The
              oral presentation included data for nine pediatric patients treated with RP-L102, Rocket&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">ex vivo</font> lentiviral gene therapy candidate, in the ongoing
              clinical trials. RP-L102 demonstrated a highly favorable safety profile with all subjects being treated without conditioning and with no sign of dysplasia or other concerning features. RP-L102 showed evidence of preliminary engraftment in at
              least six of nine patients. A clinical update is anticipated at the 63<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> ASH Annual Meeting being held December 11-14, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Pyruvate Kinase Deficiency (PKD):</u></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze242cfcb91e441b98aa2c9b682d62644">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presented incremental updates from RP-L301 Pyruvate Kinase Deficiency (PKD) program at ESGCT. </font>The
              oral presentation included<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>data from two adult patients treated with RP-L301, Rocket&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">ex vivo</font> lentiviral gene therapy candidate, in the ongoing Phase 1 trial. The safety profile of RP-L301 appears favorable with no infusion-related serious adverse events at up to 9 months post-infusion. Both
              patients have normalized hemoglobin, improved hemolysis markers and no red blood cell transfusion requirements post-engraftment, as well as no hospitalizations post-hospital discharge. A clinical update is anticipated at the 63<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>
              ASH Annual Meeting being held December 11-14, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div> <img src="image00001.jpg"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e60f95e64a14ae3a447c80d27f6686a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Published peer-reviewed studies supporting scientific rationale for clinical results observed to
                date in RP-L301 trial. </font>&#8220;Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment&#8221; was published in <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Molecular Therapy: Methods &amp; Clinical Development</font>. The studies demonstrate that in the murine model of PKD, reversion of the phenotype is seen when at least 20% of hematopoietic
              stem/progenitors are corrected, with comprehensive reversion seen when at least 30% of these progenitors are corrected. This provides meaningful scientific rationale for the clinical results that have been observed to date for the first two
              patients who have received RP-L301.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Infantile Malignant Osteopetrosis (IMO):</u></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1991613a11b34189949d17ba585b9ad1">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presented preclinical data supporting ongoing RP-L401 Infantile Malignant Osteopetrosis (IMO) Phase
                1 trial at ESGCT.</font> The Phase 1 trial is designed to assess safety and tolerability, as well as preliminary efficacy, of RP-L401, Rocket&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">ex vivo</font>
              lentiviral gene therapy candidate. A clinical update on the Phase 1 trial is anticipated later in the fourth quarter.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Anticipated Milestones</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb96479e6925a4d108a848b85953587c6">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Fanconi Anemia (RP-L102)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e1714fefd354df7b848e8475667b311">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Updated &#8220;Process B&#8221; data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa407d82272b49348dd38e9d0f72563a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">LAD-I (RP-L201)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z205eda8db3f7431db94953fedef5ef00">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Longer-term Phase 2 data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z696e19032ff84705b65f80060f99ed19">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Danon Disease (RP-A501)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ec3afe57c874d48abe60390ba568f08">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Longer-term Phase 1 data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87d0f8dbb1414d1281a43588351fb45c">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">PKD (RP-L301)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze36cf7f3e8554ce8b8fcb7f4ffc8977c">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Longer-term Phase 1 data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze8af1b4e6ac046ecb12b751b360f1dd2">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">IMO (RP-L401)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9d63c3ec36ff43788c14532b2b309ee4">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Phase 1 clinical update (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Third Quarter Financial Results</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d358abff5ae4e5da1a46f7e1fd20218">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Cash position.</font> Cash, cash equivalents and investments as of September 30, 2021, were $421.5
              million.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd5391453e5d84daa830da3414f24a49f">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">R&amp;D expenses.</font> Research and development expenses were $40.0 million for the three months
              ended September 30, 2021, compared to $21.7 million for the three months ended September 30, 2020, due to increase in manufacturing and development costs, an increase in new research agreements of $7.6 million in non-cash expenses, increases
              in compensation and benefits due to increased R&amp;D headcount, and an increase in non-cash stock compensation expense.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2380be96211d42b2a0ebd7e88b3b4d61">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">G&amp;A expenses.</font> General and administrative expenses were $9.7 million for the three months
              ended September 30, 2021, compared to $5.7 million for the three months ended September 30, 2020, due to an increase in non-cash stock compensation expense, an increase in compensation and benefits expense due to increased G&amp;A headcount
              and an increase in commercial preparation expenses.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div> <img src="image00001.jpg"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51d0d9cf771c4429bc342933746423f7">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Net loss.</font> Net loss was $50.1 million or $0.79 per share (basic and diluted) for the three
              months ended September 30, 2021, compared to $29.1 million or $0.53 per share (basic and diluted) for the three months ended September 30, 2020.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdaa356c1499a46468b2e795921db3ee2">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Shares outstanding.</font> 64,442,601 shares of common stock were outstanding as of September 30,
              2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Guidance</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Rocket expects its balance in cash, cash equivalents and investments of $421.5 million as of September 30, 2021 to fund its operations into the second half of 2023,
      including the continued buildout and initiation of AAV cGMP manufacturing capabilities at our Cranbury, New Jersey R&amp;D and manufacturing facility and continued development of our five clinical programs.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Rocket Pharmaceuticals, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare
      childhood disorders. The Company&#8217;s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using
      lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
      genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening
      anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket&#8217;s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For
      more information about Rocket, please visit <u>www.rocketpharma.com</u>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Rocket Cautionary Statement Regarding Forward-Looking Statements</div>
    <div style="background-color: #FEFEFE;">
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Various statements in this release concerning Rocket&#8217;s future expectations, plans and prospects, including without limitation, Rocket&#8217;s expectations regarding its
        guidance for 2021 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant
        Osteopetrosis (IMO) and Danon Disease, the expected timing and data readouts of Rocket&#8217;s ongoing and planned clinical trials, Rocket&#8217;s plans for the advancement of its Danon Disease program following the lifting of the FDA&#8217;s clinical hold and the
        safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other
        federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan,"
        "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket
        cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket&#8217;s ability to monitor the impact of
        COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket&#8217;s ongoing trials, our expectations regarding the delays and
        impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing
        and progress of pre-clinical studies and clinical trials of its product candidates, Rocket&#8217;s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and
        unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed March 1, 2021 with the SEC. Accordingly, you should not
        place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
        future events or otherwise.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left;"><img src="image00001.jpg"></div>
    <div style="text-align: center;"><font style="font-weight: bold; font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: center;">
      <div style="text-align: left;">
        <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Selected Financial Information</div>
        <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Operating Results:</div>
        <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">(amounts in thousands, except share and per share data)</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z727c93f06c074265a3c84067570b72ec" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; font-size: 10pt;" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="6" rowspan="1">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; text-align: center;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">September 30,</div>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="6" rowspan="1">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Nine Months Ended</div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; text-align: center;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">September 30,</div>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; font-size: 10pt;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Operating expenses:</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Research and development</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">39,975</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">21,657</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">93,315</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">55,345</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">General and administrative</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,671</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,730</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">29,600</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">19,720</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Total operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">49,646</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">27,387</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">122,915</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">75,065</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Loss from operations</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(49,646</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(27,387</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(122,915</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(75,065</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development incentives</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Interest expense</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(534</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(1,967</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(2,514</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(5,326</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Interest and other income net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">806</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">518</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,218</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,913</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Amortization of premium on investments <font style="font-family: 'Times New Roman';">-</font> net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(744</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(244</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(2,111</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(306</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(50,118</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(29,080</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(124,822</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(78,784</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss per share attributable to common shareholders <font style="font-family: 'Times New Roman';">-</font>
                basic and diluted</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(0.79</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(0.53</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(1.99</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">$</font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">(1.43</font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">)</font></div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; text-indent: -9pt; margin-left: 9pt;">Weighted-average common shares outstanding <font style="font-family: 'Times New Roman';">-</font> basic and diluted</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">63,825,461</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">55,188,956</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">62,828,612</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">55,077,254</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; font-size: 10pt;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; font-size: 10pt;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; font-size: 10pt;" colspan="2">
              <div> </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">September 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; font-size: 10pt;" colspan="2">
              <div> </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2" class="cftcurrcell" rowspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2" class="cftcurrcell" rowspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Cash, cash equivalents and investments</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">421,459</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">482,719</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">530,241</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">590,824</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">44,583</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">87,305</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;" rowspan="1">Total stockholders' equity<br>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" rowspan="1">485,658<br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" rowspan="1">503,519<br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contacts</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Kevin Giordano</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Director, Corporate Communications</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>kgiordano@rocketpharma.com</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investors</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Mayur Kasetty, M.D.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Director, Business Development &amp; Operations</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>investors@rocketpharma.com</u></div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rckt-20211103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://rocketpharma.com/20211103" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:rckt="http://rocketpharma.com/20211103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20211103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20211103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rckt-20211103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rckt-20211103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rckt-20211103.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://rocketpharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !? .0# 2(  A$! Q$!_\0
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M2WEA8)+$YS@D9X/<?E6E+$1J:=3EQV5U<)[V\>_^9T]%%%;GF!1110 4444
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MD+'"]0_O@YR*]DH **** "BBB@ HHK)\3>(](\,:>+W7KZ*RMBP16DR2S>@
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MO^"9[+1/'^F3^+[&62TBG#7,,ZD$9'#LI&2 2&QW ]ZZ#]GO2++6?B=8PZE
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MN\H 0=OJ,@9'N* -6N%\2_"?P9XBNWN[_1HTNG)+2VSM"6)ZDA2 3[D9K?\
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MO$EV]WJ.CQK=R$L\UN[0LY/4MM(!/N1FLW3?@CX$L9EE_LAKEUY'VBXD=?\
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MT>%+>-H6\N/-R26R"S@Y"]-HP>:G^&.1X1A!X_?SX&TK_P M6['I]*ZK&:*
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10030396_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rckt-20211103.xsd" xlink:type="simple"/>
    <context id="c20211103to20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20211103to20211103"
      id="Fact_944bc0aef3cb4174950264ab04becc74">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20211103to20211103"
      id="Fact_b48c9520a2c348a1b56780cdea1ae5fa">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityCentralIndexKey
      contextRef="c20211103to20211103"
      id="Fact_98d2cd2eb343466ca3784513905cfb53">0001281895</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20211103to20211103"
      id="Fact_6f1d23abc01e4157aae70e9b707453c4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20211103to20211103"
      id="Fact_f8fc90c4ce9342718b0519da845612b4">2021-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20211103to20211103"
      id="Fact_dad36ab69fb6437bb28e010c1f63bf51">Rocket Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20211103to20211103"
      id="Fact_d68075168c8a45ef938be564446fd2bc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20211103to20211103"
      id="Fact_a908c921b7de4f2f8ad25225f0f4033a">001-36829</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20211103to20211103"
      id="Fact_6c07395c000a405e980479ccffceeb60">9 Cedarbrook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20211103to20211103"
      id="Fact_b5c7a0d9cc8d44eba37c3ee2714e05d0">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20211103to20211103"
      id="Fact_bd44b78ba0a34ad7a78e531c30b1fca6">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20211103to20211103"
      id="Fact_e888262174d04a839250db071dba54fa">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20211103to20211103"
      id="Fact_c4605771fcfe43c799a64fbfd1abf696">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20211103to20211103"
      id="Fact_3dbba35d95a5497da2b37a5084e4a45b">440-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20211103to20211103"
      id="Fact_ad119c79dd3a4b049bd1e0e15d1ae439">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20211103to20211103"
      id="Fact_20e409d334da43de86e3e6cc82572481">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20211103to20211103"
      id="Fact_dcf8ca17e5374636a3d7e1c0d69e47b3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20211103to20211103"
      id="Fact_a469b6f38976430fb924a7f149b36df8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20211103to20211103"
      id="Fact_d5bf7b018c9c4b32948d10bea750f018">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20211103to20211103"
      id="Fact_f6e5f288615a45a3b079e3cb0d3af6a9">RCKT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20211103to20211103"
      id="Fact_40553ed7e99e47f3b43f134a67a44e38">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20211103to20211103"
      id="Fact_4b8fa9b47df24d6fb673ddda66431986">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140382850036296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rocket Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Cedarbrook Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-9100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001281895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCKT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  AKF-3'#AEZC\!   \ @
M#P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^0!-0BU1$N)0^D*H6E8K[
MDG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_2
M36P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R '<(Y
M_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3 QFU+BLX5>C(,=D",
MY1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!
M<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L
M>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI
M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ (:YC4R0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  AKF-3I-(H7>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  A
MKF-3F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "&N8U/?ARG"-@0  $40   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  A
MKF-3GZ ;\+$"  #B#   #0              @ %Z#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( "&N8U.7BKL<P    !,"   +              "  58/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "&N8U,<.&7J/P$  #P"   /
M          "  3\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  AKF-3
M)!Z;HJT   #X 0  &@              @ &K$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  AKF-399!YDAD!  #/ P  $P
M        @ &0$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  #:$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10030396_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rocketpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10030396_8k.htm">brhc10030396_8k.htm</File>
    <File>brhc10030396_ex99-1.htm</File>
    <File>rckt-20211103.xsd</File>
    <File>rckt-20211103_lab.xml</File>
    <File>rckt-20211103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10030396_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10030396_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rckt-20211103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rckt-20211103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rckt-20211103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rckt",
   "nsuri": "http://rocketpharma.com/20211103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10030396_8k.htm",
      "contextRef": "c20211103to20211103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://rocketpharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10030396_8k.htm",
      "contextRef": "c20211103to20211103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-21-036477-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-21-036477-xbrl.zip
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M="*CV[6V]<?B6A<>+^1U>I?4 _$.\XC!@4L^QUA08GO,%@(<,BP,AV_"LR[
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M;0P*0@IV:]XMBY64WXP9GZTZF]?<*E EU=FQA''_:UL37'N[D>:ENXS.<C%
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M(2.#@J#Z)*PR/PO*W#NOHT>,"U8>(.D4*S;JXJJ: U\<R2E^@-"I%%2'4NX
MOJ%L1/\-72WFET!Q1&@4%[W4_28YR@I6[ $S9<G62'&U8EW)W-F1%G@!0#J]
MSD0-N\*-Y4[!E=N42F=KCI'IXC+4G@HV@DBJ;&*L94YM202% &,(T@5-ET=(
MV3P-V8CU2R(>*2OOMGI[MCIH&>;/9*MG%ED?E5#ZO3#5I3K+?B+[O/PP -]=
M[.O[6NGR^>R_2/#T"7%2@HH;JZCL,V"#;=B!^R\Q#H*FV>KG@\:1LKH';7+T
MC#!S\%W%\B\U.NL5Z&P/<6VG%F^=V.Y:U<N,]PMQQ#3P3S.Z71A(B50@ -P
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MS9#O>>]8.VNC3V0DR2VZZI/^'OIZ\B92_CA]^EHB_F8@^GU(OK,A*3^H-CJ
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M_%^Y0"5^\?;T;& A#\/"6$]ML3C0*3W/"QH 'I<T9M6"S(N<PS,RK%CWE(2
MW,CS)& 9BT'J"\[ZHD>:IJ1DYRQ;=G>15%-"*\!06E;$(3.8V;3$8<5YFN87
MI)Y+BOWU!VMH/M_]PAPDRRU%<5?\=?3RE5S:I1JNYQ&(.B(6X%PR5V*_*MJP
MN*>_GPJP^QSBJB<Q(,)GP+(DSTK)/>3UJ<$9[PW_X.,?9_CBT &X//W\.SG-
MLAJ8ZAUC%5@&NYNC9+(=MM\#7KL:RW_-(C3$?J$IZ"5&/D^!YD),?W1MZ\0C
M[Y(TA97#17M%R^ES_C?Y5&<7=$%^_39GH>"#*B?V[[S5T7/;(=N!=&%K[070
M.ZK^U:?3][_\X]/_&>3]WTB#43!'"X1PZ[V]S\_9+ "CP3&$*'5[K"^Q/0SR
M)@M/7CRM7Y+C]Z>?ST[__HQ\>O7'ER<&H0U: S. 8<75 \T6A$;G:), %U!<
MYHI-"B[;*)EE#<^"S8)Z8)[,62JUR 3P'GHDU905=)[ E.*\( 4MH-EIDD;3
M/(](E)3<S(1157D$[%)(PRA65I "ET(:0]@(-$G^+6TF)KCS,YM7DAZF) @.
M3@$2<">^]$K,YZ>2?&6+Y6@C4$%I/D>-" ,)T/$ ,"+Y'$9>(289LC&@!W8&
M"\7*"NSB\F1/W(NK;)O/_PEH"O1DW\*$+T>0UQ6?:%D5.0QT+FU$<L' QH\8
MBBA^77&S4Y&0\N^7AEK5,MY(7A=KQAA?A%50EPV#@AY$.?Q^/#P9,<LAYY.G
M7R=/U")>9O\9?#[ M25-(O(;K0MZ#D!#IP9Y=W)V8I!7TX3%@"4L!"X^9^1#
M#"H#AHYC:G/Y"9&4 :TQP^G7$3[#)\'H3()/B;91"M02RRO #(?_^@R43C6%
MUR93<C%-PBE2YH(!C3E_ X*5%TE<I<BH99Z>,_Y:8^-,0385KPGZ"-(A]R #
MSSCI2T6.*1KU"Y+,D.=!9Y*+O/B*[P=L2M,81RY:4=;1"9$K/F&T0$ZLYXU
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M(/8)F!88&9*M\):7/<=%/L//8;"K[1K-5!1Y2V3PB $W OPA"].K713H)$T
MT&FQ4'-?\U:2KFN"@P#2\_7@XGB1H!,SQ>6D490@H+3='CX=-0FYC)+"@BY#
MYT4)8BSY#AKG:EKQ'N?#*I\_)ZBI!BH.9*WP6SF#Y0;#[^AE$;UX"JV]W& C
M<]EE(5>2+0;BPP>S0$%#%P=*!02O01_G60*MLEE"&Z-<2>()0<AM@%XA+V<Y
M@= K (S&(<P5QQ6!4@@%$//UX[I8V!H1"? 1_"5-8C8(IU3\%M8(W>>L95W
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ME34HKW.NLZM<J":>>4*:AC 4 !^<OH@8X>*7POGC690V,\S!E\JKQ1Q\NX]
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MK)+W6;:M/RR[)+V%='U5"G&/J8+LZA]02P,$%     @ (:YC4_.$* 6!"
M<E@  !4   !R8VMT+3(P,C$Q,3 S7VQA8BYX;6S-G&MOVS84AK\/V'_@O"\;
M4,>Q#0Q+T+C(TJ0(EB9!DF(W#(4LT8XP60PH.7'^_4A)M$7RD%(J2A8*M K/
M>U[>GB/)2N7W'S:K"#UCFH0D/AF,#PX'",<^"<)X>3)8)T,O\<-P\&'V_7?O
M?Q@./^$84R_% 9J_HO./GT[O%F'$I FZO;MAAQC]>G#(_Z#?*/$"&@9+/!SR
M9*;Z[YC_-?<2C%BG<7*\2<*3P6.:/AV/1B\O+P<OTP-"EZ/)X>%X].?GJWO_
M$:^\81@GJ1?[>("8_CC)&J^([Z79B$OIFSF-A,%TM.W+J. _#85LR)N&X\EP
M.C[8),&@&"(/U^A$R#>:OIC3^.CH:)1%MU)F%%JLM]-FJX=0OGZ41/@.+Q#_
M]\O=I3'[:,05HQBG5]X<1ZS++#U]?<(G@R1</458M#U2O(!](DJW-GQUCOCJ
MC'_AJ_/CSGG49'A+CM(#2;W(S3@S/WVL6C?-!WWM:FEM0[YVN<JLQ'$'JUSJ
MIOF@;S$-27 >!^T/7.W*U>#O4X]V@(K>6?,)M#]J8*@1;[IB1U*_>)/B.,"!
MZ)E[6\Z=6=?9R39SWGH37W*-^%6$4'TZ"7/-'!/L'RS)\RC (7.>C/G!D!]D
MLV _?#TC[.)Y.D]2ZOFI<,HF<3( 8VF8\K$KL9$\4)XO#97BA*RICY4>M!%\
MC>;1FQ9)VN-\:";35<2ZY;<%.!Y^N1^@,#!I9UD3^D<T_OM^M!NU/M-3*N^+
M1WTQ)'98,8U",?()NU@^I4-I1@M*5J9](!7+5ZQ&YG>,)!E*"3+DCEHG[B/Q
MURL<IP_,4<$!"A73D$,-<"L;N:(-\#3!IDEGH@7QIOV"!JX_L:^;C%E9)2C3
M,]N'[ \:INR4>T96JW4<YC?;B4*#55-,RZ!IP!_HZ I$F[F)2'/.K @A.;9?
M1NV[1FHNLDPM*!?X6KS:Y_B>1*$?INPCZF=VPT%#+U*0,@N**4*"!OCJ=J[8
M-3J;P#4DS';M2 3VBZQECTB=595AU;6"5)-+^YC>4LSK [,ER,[T_&:7WBP6
MF"H(50N+R=J$#? UV[K"N+('$\X5B3,6'_HE <H5*)/L%_ :NTK>LOXR\.8<
M 7Z5:^<%<)DD:TQKEX%1#A<#('=7$IIY2X5AZJ=F><#I>I'DNO[6BGGKX8JQ
M;H^U;K1,0_48>FB_ADY9[P$?P47D+150P5@Q7276H!0D)U?<0Z8FR'7M;-N$
M>-M^V85W@50LGDRE)!,( KG=/8BX"!/?B_["'KU@+>JGQ J5\GA"4SEX4J%X
MNGYH =M7/;^ LG:/,O(HXF&4Q?OQ7,.TAZ3V@L-/.Y0$]<$'Z-<UW_D3]FK"
M 1W(N*1S1GG)M1W.]0[JD:[F::SG@O[1#NTGR+MAZ6W$EU)@YC7/[JC?_D+L
M(_LL;" >U"BT*QH'I$N.KBF'S*L(UW-V=!=8LR#BT7Z0#>\;J;G,,-&27*49
M\&J?Y/.8C?3U#B]#_@N:.+WV5BI6-DDQ35C2 &/(T!7%%F\3Q,:461Y!NQ#B
ML?T2;-TP4F^!97XAM<#7[-05O6>L>*@77;(/DYO?\2N(KT$C\:MI&@.L.+HE
M&#:W(PSE"(:+&,J"B$7[0+%IWTC-988X5N0RR*!75R1?A!&^7J_FVK,\4UCB
MMQQNC.[.S"VUFJ\=6$4N6.7-*&_O Z7 QI#JQ838W"EE+%6'KHA\\#:7 2N)
M<%'\5M*"9X568M6H;0RNP=DMQ?9.[$C;<@7?3(-D48]HK]IG\L;M@.K D"87
MA=6[JPJYC'U"GPC-!G"?LGOW,[)FUY#7,Q+ M]*U,J1JJ<AH7#-6?[>54Z<K
M>_U4.X@JDI3O4*9%A*)"CWA"'PJJ'A#DFW8,*BYKLEQB-?KIJM#.5Y@NPWCY
MB9*7]/&,K)Z\&+[9MRJEPC(H&Q<4Z.NVD&Q=V O(G"D*1RA0+D&%I@^U8M];
M\J9-@&H#3))KPN+;52V<!@%C,"G^N0IC/ 8KP:*3Z@#4-:X"P-5M#9@[L%>
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MQ1@+T\# 8]<E&<>E:K@HV.X!9GOW0'K "R*S2?D=2DRRZR!%>>P0>%0[I-+
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MCUN'5!P7J^Y!,7UJ1^[<+Y7J5ER0_WZ^L\AO\M^U/_T'4$L! A0#%     @
M(:YC4V1)I%!0$0  N6,  !,              ( !     &)R:&,Q,# S,#,Y
M-E\X:RYH=&U02P$"% ,4    "  AKF-3^KW'NG8C  "3JP$ %P
M    @ &!$0  8G)H8S$P,#,P,SDV7V5X.3DM,2YH=&U02P$"% ,4    "  A
MKF-33$I>JE8#  !_#P  $0              @ $L-0  <F-K="TR,#(Q,3$P
M,RYX<V102P$"% ,4    "  AKF-3\X0H!8$(  !R6   %0
M@ &Q.   <F-K="TR,#(Q,3$P,U]L86(N>&UL4$L! A0#%     @ (:YC4V-@
M:!OG!0  ]SX  !4              ( !94$  ')C:W0M,C R,3$Q,#-?<')E
:+GAM;%!+!08     !0 % $L!  !_1P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
